

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number  
**WO 03/103691 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 33/34**, 33/32, 33/24, 31/56
- (21) International Application Number: PCT/US02/18223
- (22) International Filing Date: 7 June 2002 (07.06.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 09/876,875 (CON)  
Filed on 7 June 2001 (07.06.2001)
- (71) Applicant (for all designated States except US): **CHIOU CONSULTING, INC.** [US/US]; 6539 Manor Drive, Burr Ridge, IL 60521 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CHIOU, Win, L.** [US/US]; 6539 Manor Drive, Burr Ridge, IL 60521 (US).  
**CHIOU, Linda, L.** [US/US]; 6539 Manor Drive, Burr Ridge, IL 60521 (US).
- (74) Agent: **MERCHANT & GOULD P.C.**; P.O. Box 2903, Minneapolis, MN 55402-0903 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF APHTHOUS ULCERS AND HERPES SIMPLEX LESIONS

(57) Abstract: Disclosed is a topical method for providing adequate analgesic, anti-inflammatory, antimicrobial and tissue-regenerating activities for the hitherto most effective prophylaxis and treatment of aphtous ulcers and herpes simplex lesions and for the effective treatment of burns and other oral mucosal ulcers comprising topically administering to the affected tissue an effective amount of a composition comprised of one or more safe and efficacious polyvalent metal compounds such as magnesium sulfate, preferably with one or more safe and efficacious anti-inflammatory compounds, such as a novel ultra-low-strength hydrocortisone (acetate), that potentiate the activities of polyvalent metal compounds. Both the ionic and neutral moieties of the polyvalent metals are pharmacologically active; water-soluble and water-insoluble polyvalent metal compounds are both therapeutically effective.



WO 03/103691 A1

## **Compositions and Methods For the Prophylaxis and Treatment of Aphthous Ulcers and Herpes Simplex Lesions**

### **Background**

5           Aphthous ulcers, also known as canker sores or ulcerated stomatitis, are a common oral lesion. Approximately 20% of the population will suffer from the annoyance and irritation of a canker sore in their lifetime. (Gastrointestinal Disease: Pathophysiology/Diagnosis/Management, 5th edition, M. H. Sheisenger et al., eds., W.B. Saunders Company, Philadelphia, p. 273 (1992).) Canker sores  
10 are generally round, clearly defined, painful, shallow ulcers in the lining of the mouth (oral mucosal surfaces). They usually begin with a tingling or burning sensation (prodromal period), followed by a red spot or bump (a swelling of the tissue) that ulcerates. The ulcers/canker sores are often covered with a grayish-white exudate and surrounded by an erythematous (inflammatory) margin. They  
15 range in size from pinpoint (minor aphthae) to over one-quarter inch in diameter (major aphthae). Canker sores usually cause discomfort and/or pain, and they may cause pain so severe that difficulties in speaking and eating result, which can lead to weight loss. ("Diseases of the Oral Cavity," In: Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics," G. S.  
20 Avery, ed., Aids Press, Sydney, Australia (1976).) Canker sores usually last from about 7 to about 10 days, but may last for several weeks.

          The cause of canker sores is unknown, but a number of conditions are believed to be associated with the disorder, suggesting that more than one cause is likely. Some canker sores are thought to be related to an abnormal immune  
25 system and are probably genetically influenced. Emotional stress and mouth injury, such as those caused by dental procedures, aggressive tooth cleaning or local trauma, such as when the tongue or cheek is bitten, are thought to trigger outbreaks. Further  
etiologic factors include immunologic, microbiologic, viral, nutritional factors,  
30 such as dietary deficiencies (especially iron, zinc, folic acid or vitamin B<sub>12</sub>), menstrual periods, hormonal changes and food allergies (to substances in nuts, chocolate, acidic foods (such as vinegar, pickles or citrus) and gluten). (Oral

Pathology: Clinical Pathologic Correlations, 3rd edition, J. A. Regezi et al., eds., W.B. Saunders Company, Philadelphia, pp. 46-53 (1999).)

Currently, there is no cure for canker sores. However, there are several palliative treatments that can soothe the sores. Commonly suggested treatments include topical antiseptics, antibiotics and anaesthetics (such as 2% viscous lidocaine or 10-20% benzocaine gel) to temporarily relieve pain. Topical application of high-potency synthetic glucocorticoids such as triamcinolone acetonide and dexamethasone has also been used ("Oral and Maxillofacial Pathology by B.W. Neville et al., pp. 236-239 (1995)). Because of their potential serious adverse effects, the use of such glucocorticoids requires a prescription.

Recently, amlexanox oral paste 5% (Aphthasol® from Block Drug Company) was made available as a prescription drug to treat aphthous ulcers. However, its efficacy is still quite limited. For example, after 4 days (four times daily) of continuous treatment, complete resolution of pain and complete healing of ulcers was achieved in only 60% and 37% of patients, respectively.

U.S. Patent No. 5,981,499 by Hau discloses a topical method to deliver a supratherapeutic level of antibiotic to shallow aphthous ulcers to inhibit opportunistic pathogenic bacteria in the oral mucosa that is substantially higher than levels achieved by oral, intramuscular or intravenous administration of antibiotic. In the method disclosed by Hau, the medicament is in the form of a powder or troche and includes a dry dosage of antibiotic such as one of the known penicillins, beta-lactam antibiotics, tetracyclines, aminoglycosides, cephalosporins, macroglides, vancomycin, bacitracin, chloramphenicol and their salts and mixtures thereof. Hau further discloses that the powder or troche includes an effective amount of a salt or oxide of a polyvalent metal compound such as magnesium, zinc, calcium, aluminum, bismuth, titanium, and copper and mixtures thereof to form a protective barrier over the aphthous ulcer. Hau discloses that the presence of the antibiotic prevents most microorganisms of the normal flora from surviving or multiplying, permitting tissue regeneration processes to occur under the protective barrier coating. Hau emphasizes that

control of infection is essential for promoting the healing process. As disclosed by Hau, the troche or powder may be mechanically directed in place, for example, by the fingers. Once in contact with the aphthous ulcer, the troche or powder may be held in position by the tongue for about 5 to 15 minutes. Hau  
5 discloses that painful symptoms improve 24 hours after treatment, ulcers display visible signs of healing within 2 days, and canker sores heal in about two to four days.

However, the methods disclosed by Hau are limited in several ways. For example, it can be difficult or impossible to hold the dosage form for 5 to 15  
10 minutes in hard-to-access areas of the mouth. Additionally, administration can be difficult or impossible in most infants and small children. Another serious drawback of the methods disclosed by Hau are that some patients may be allergic to antibiotics. Also, the development of antibiotic-resistant microorganisms can occur as a result of the methods of Hau.

15 Another type of common lesion is caused by the herpes simplex virus (HSV) (Neville, B.W. et al., Oral & Maxillofacial Pathology, W.B. Saunders Company, Philadelphia, 181-186 (1995)). There are two types of herpes simplex virus, HSV-1 and HSV-2. Symptoms of HSV-1 infection occur mainly in the pharynx, intraoral sites, lips, eyes and skin above the waist, while those of  
20 HSV-2 occur mainly on the genitalia and the skin below the waist. The most common recurring site for HSV-1 is the vermilion border and adjacent skin of the lips, known as herpes labialis ("cold sore" or "fever blister"). An oral HSV outbreak occurs in about 15 to about 45 percent of the population (Neville et al., p. 183). Usually, from about 6 to about 24 hours before the lesions develop,  
25 prodromal symptoms appear (such as pain, burning, itching, tingling, a localized warmth and erythema of the involved area; these symptoms being referred to as "pre-ulceration" or "prelesion" symptoms of herpes simplex lesion herein). Multiple small, erythematous papules may develop and form clusters of vesicles. The vesicles may rupture and crust in about 2 days. Abolishment of pain and  
30 healing of ulcer, or lesion usually occurs within about 7 to about 10 days.

Currently, there are no commercial drug products that can effectively treat or cure herpes simplex lesions. Topical pastes or gels containing certain specific analgesics such as benzocaine or benzyl alcohol have been commonly available as over-the-counter products to temporarily relieve the pain of the disease. Abreva® (docosanol), a topical over-the-counter product marketed by GlaxoSmithKline Pharmaceutical Company, was reported to perform only slightly better than the placebo (mean healing time of 4.1 days versus 4.7 days for placebo in one study) in treating cold sores (The Wall Street Journal, January 19, 2001). Prescription products containing topical antiviral drugs, such as Denavir® (penciclovir cream), were also reported to be of limited value in treating herpes simplex lesions (The Wall Street Journal, January 19, 2001).

Thus, current topical treatments for aphthous ulcers or herpes simplex lesions generally require several applications a day and take several days to abolish the pain and inflammation and/or heal the ulcer/lesion. Additionally, there are no known effective topical treatments for prevention of the formation of ulcers/lesions (e.g., prophylactic). Thus, there is currently a need for an effective treatment of lesions, including herpes simplex lesions and aphthous ulcers. Specifically, there is a need to develop an effective, inexpensive, simple, safe, rapid, convenient, and preferably nonprescription-required method to prevent and treat such lesions.

### Summary

Applicant has unexpectedly discovered that polyvalent metals and salts, oxides, hydroxides and/or organic complexes thereof provide combined analgesic, anti-inflammatory, anti-microbial and tissue-regenerating properties, and thus, are useful for preventing and treating aphthous ulcers and for preventing and treating herpes simplex lesions. The disclosed compositions and methods represent the hitherto most safe and efficacious prophylaxis and treatments (including abolishment of pain and inflammation as well as regeneration of ruptured tissue) of pre-ulcerous/lesion symptoms, aphthous

ulcers and herpes simplex lesions. Both ionic and nonionic (neutral) moieties of the polyvalent metals are pharmacologically active.

The present invention provides for the use of an effective amount of a salt or oxide of one or more polyvalent metals to prepare a medicament (a medicinal substance or agent that treats or prevents or alleviates a medical condition such as a disease and/or its symptoms) useful for: preventing an aphthous ulcer on a mucosal surface of a mammal; treating an aphthous ulcer on a mucosal surface of a mammal wherein the medicament comprises a mucoadhesive paste; treating one or more pre-ulceration symptoms of an aphthous ulcer on a mucosal surface of a mammal; treating a herpes simplex lesion on the skin of a mammal wherein the polyvalent metal is not zinc; or preventing a herpes simplex lesion on the skin of a mammal wherein the polyvalent metal is not zinc.

The present invention also provides a method for preventing an aphthous ulcer on a mucosal surface of a mammal comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals to a mucosal surface demonstrating pre-ulceration symptoms so as to prevent the ulcer.

The present invention further provides a method for treating an aphthous ulcer on a mucosal surface of a mammal comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals in a mucoadhesive paste to the ulcer.

The present invention also provides a method for treating one or more pre-ulceration symptoms of an aphthous ulcer on a mucosal surface of a mammal comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals to a mucosal surface demonstrating pre-ulceration symptoms.

Additionally, the present invention provides a method for treating a herpes simplex lesion on the skin of a mammal comprising topically administering an effective amount of a salt or oxide of a polyvalent metal to a mammal in need of such treatment, where the polyvalent metal is not zinc.

There is also provided a method for preventing a herpes simplex lesion on the skin of a mammal comprising topically administering an effective amount of a salt or oxide of a polyvalent metal to an area of skin demonstrating pre-lesion symptoms so as to prevent the lesion, where the polyvalent metal is not  
5 zinc.

The invention also provides a method for preventing an aphthous ulcer or herpes simplex lesion in a mammal comprising topically administering an effective amount of one or more anti-inflammatory compounds (steroidal and/or nonsteroidal) with or without an effective amount of a salt or oxide of one or  
10 more polyvalent metals to the affected mucosal or skin surface likely to suffer from an aphthous ulcer or herpes simplex lesion. Addition of an anti-inflammatory compound such as hydrocortisone acetate to a polyvalent metal compound potentiates the activity of the metal compound and reduces the chance of flare-ups of lesion. A novel ultra-low-strength of hydrocortisone such  
15 as 0.02% is unexpectedly found to be therapeutically highly effective (Example XIX). Strengths of 1.0% and 2.5% in ointments or creams are commonly available for external use.

The invention also provides the use of an effective amount of a salt or oxide of one or more polyvalent metals to prepare a medicament useful for:  
20 preventing or treating oral ulcers of a mammal resulting from chemotherapy or radiation therapy; or providing relief of pain and wound healing of burned tissue of a mammal.

The present invention also provides a method for the prophylaxis or treatment of oral ulcers of a mammal resulting from conventional chemotherapy  
25 and radiation therapy (e.g., cancer treatment therapy) comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals to a mucosal surface likely to suffer or suffering from ulcer formation.

The present invention also provides a method for providing relief of pain, inflammation, infection and the promotion of wound healing of burned tissue, as  
30 a result of fire or heat of a mammal comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals to the

affected burned tissue. When treating burn tissue, is it preferred that an effective amount (ranging from about 0.1% to about 2% preferred) of one or more polyvalent metals is administered in a solution, a liquid, a spray, or a gel, containing at least 30% by weight of glycerin, that will serve as an effective  
5 liquid protective layer for the burned tissue.

The therapeutic compositions and methods described herein provide the following benefits: (1) rapidly (within about 5 minutes to about 15 or about 20 minutes) inhibit or stop the tingling or burning sensation associated with an oral aphthous ulcer or an oral pre-ulcerous area of the mouth after a single  
10 application; (2) rapidly (within minutes) abolish the pain and irritation of an inflammatory red spot or erythematous bump (pre-ulceration symptoms) of the oral tissue after a single application; (3) completely cure the inflammatory red spot or erythematous bump (associated with pre-ulceration of the oral mucosa) of oral tissue after about one to about five applications and within about 24  
15 hours from the beginning of treatment; (4) quickly (within minutes) stop the pain associated with an inflammatory aphthous ulcer after a single application; (5) completely cure/heal the ulcerated inflamed tissue of an aphthous ulcer after about one to about five applications of the medicament within about 12 hours to about 24 hours; (6) do not require a physician's prescription; (7) are virtually  
20 free of allergic reactions (e.g., hypoallergenic and/or nonallergenic); (8) are pharmacologically safe with minimum or no toxicity; (9) do not result in the development of resistance of microorganisms to antibiotics; (10) are relatively inexpensive; (11) are chemically stable; (12) are not distasteful or unpleasant to the taste (e.g, they are pleasant to taste); (13) are easy to apply and store; (14) do  
25 not contain a high-potency glucocorticoid steroid (e.g., a synthetic steroid with an anti-inflammatory potency that is many times more potent than hydrocortisone, or cortisone, both being endogenous, low-potency steroids); or (15) are able to simultaneously provide the needed analgesic, anti-inflammatory, anti-microbial and tissue-regenerating properties for controlling, preventing, or  
30 treating pre-ulceration and/or post-ulceration symptoms related to aphthous ulcers and/or herpes simplex lesions.

### Detailed Description

The present invention includes methods to generally abolish the pain associated with pre-ulceration (e.g., stinging or burning sensation, painful red spots, painful erythematous bumps and mouth injury) and post-ulceration conditions (e.g., painful and inflammatory lesions/ulcerated skin and/or ulcerated mucosal surfaces) of aphthous ulcers or herpes simplex lesions of a human after one application of a medicament comprising an effective amount of one or more salts or oxides of polyvalent metals. The present invention also includes methods to rapidly (within about 12 hours to about 24 hours) heal an inflamed aphthous ulcer. Therefore, methods of the present invention provide the hitherto most efficacious treatment and prevention (prophylaxis) of aphthous ulcers and symptoms associated therewith. The medicaments of the invention include, for example, an effective amount of one or more polyvalent metal compounds, such as magnesium sulfate, without or preferably with an anti-inflammatory compound, such as hydrocortisone acetate. In one embodiment, the medicaments comprise a mucoadhesive agent to form a mucoadhesive paste. The medicaments and methods of the invention are also effective to treat and/or prevent herpes simplex lesions (see Example XVIII), oral ulcers resulting from chemotherapy or radiation therapy (e.g., cancer treatment therapy), and to treat tissue which has been burned by fire or heat.

As used herein, the term "lesion" or "ulcer" includes lesions or ulcers of the lips and adjacent skin, the tongue, the gums and other internal tissues of the oral cavity, and the pharynx. The lesion or ulcer can be an aphthous ulcer, an aphthous-like ulcer, a lesion of the pharynx, or a lesion associated with herpes simplex virus, gingivitis or stomatitis. The lesion or ulcer can be of the mucosal, submucosal, epidermal, dermal and/or subcutaneous tissue.

"Treating," as used herein, includes ameliorating the symptoms of, curing, and preventing the development of a given disease or condition. Preferably, the disease or condition to be treated or prevented is an aphthous ulcer or a herpes simplex lesion. As used herein, the term "prevention" includes

the prevention (i.e., prophylaxis) of ulceration in an area demonstrating pre-ulceration symptoms.

As used herein, the phrase “pre-ulceration symptom(s)” of aphthous ulcers refers to stinging, burning, pain, inflammation, red spots, erythematous bumps and mouth injury prior to the formation of ulcers in the mouth.

As used herein, the phrase “post-ulceration symptoms” refers to the pain, inflammation and ruptured tissue of the ulcer or lesion.

As used herein, the term “bioadhesive” refers to a substance, such as a paste or biologically compatible cement, that provides or promotes adhesion to a biological surface. The term “mucoadhesive” refers to a substance, such as a paste or biologically compatible cement, that provides or promotes adhesion to mucosal surfaces. Bioadhesive and mucoadhesive agents include, but are not limited to, carboxymethylcellulose or derivatives thereof, Carbopol® ULTREX-10 (a polyacrylic acid polymer used as a thickening, bioadhesive or mucoadhesive agent), polyacrylic acid polymer, gelatin or a mixture thereof. The bioadhesive substance and/or the mucoadhesive substance will allow for prolonged (about 1 to about 8 hours) direct contact between the tissue (biological surface) and the medicinal composition, and thus, allow for a continuous and effective delivery system.

As used herein, the phrase “thickening agent” refers to any substance/material used to thicken a medicinal composition. Thickening agents include, but are not limited to, carboxymethylcellulose or derivatives thereof, Carbopol® Polymers, polyacrylic acid polymer, gelatin or a mixture thereof.

The phrase “effective amount” refers to that amount of a compound which is sufficient to effect treatment when administered to a mammal in need of such treatment or prevention.

As used herein, the phrase “polyvalent metal compound” refers to any organic or inorganic polyvalent metal compound that has the beneficial therapeutic properties described herein. Polyvalent metal compounds include bismuth compounds, zinc compounds, magnesium compounds, aluminum compounds, calcium compounds, titanium compounds, iron compounds, copper

compounds or a barium compounds. In one embodiment of the invention, the polyvalent metal is not aluminum. In another embodiment of the invention, the polyvalent metal is not a Group IIIa element, such as boron, aluminum, gallium, indium, or thallium.

5           Applicant has discovered that polyvalent metals have beneficial properties including analgesic, anti-inflammatory, anti-microbial and tissue-regenerating properties for controlling, preventing, or treating pre-ulceration and/or post-ulceration symptoms related to aphthous ulcers and/or herpes simplex lesions. Thus, according to the methods of the invention, an amount of  
10   a polyvalent metal effective to produce the stated therapeutic activity is administered. When a polyvalent metal salt is administered according to a method of the invention, the counterion to the metal does not contribute significantly to the stated therapeutic effect. Accordingly, as used herein, the term "polyvalent metal salt" preferably excludes salts wherein the counterion to  
15   the metal would contribute significantly to the stated therapeutic effect when administered according to the method of the invention. In one embodiment of the invention, the "polyvalent metal salt" is an inorganic or organic salt or complex. In another embodiment of the invention, the "polyvalent metal salt" is an inorganic salt. Both water-soluble (solubility greater than 1 in 50)  
20   polyvalent metal compounds, such as magnesium sulfate and ferric chloride, and water-insoluble (solubility less than 1 in 1,000) polyvalent metal compounds, such as bismuth citrate and magnesium hydroxide, are therapeutically effective (see Examples). Thus, both ionic and nonionic species of the polyvalent metals are therapeutically effective.

25           In one embodiment of the invention, the therapeutically effective compound is selected from the group consisting of bismuth, bismuth subsalicylate, bismuth chloride, bismuth oxide, bismuth subcarbonate, bismuth subgallate, bismuth subnitrate, bismuth phosphate, bismuth aluminate, bismuth salicylate, bismuth tribromophenate, bismuth dipropylacetate, bismuth citrate,  
30   bismuth subcitrate, bismuth ascorbate, bismuth subcarbonate, bismuth tartrate, and colloidal bismuth subcitrate.

Additionally, the active ingredient in Pepto-Bismol<sup>®</sup> (bismuth subsalicylate) and Bismatrol<sup>®</sup> (bismuth subsalicylate) is bismuth subsalicylate. Thus, Pepto-Bismol<sup>®</sup> and Bismatrol<sup>®</sup> are examples of compositions that comprise a bismuth compound.

5           In another embodiment of the invention, the therapeutically effective compound is selected from the group consisting of zinc, zinc sulfate, zinc acetate, zinc gluconate, zinc chloride, zinc carbonate, zinc oxide, zinc oleate, zinc stearate, zinc propionate, and zinc undecenoate.

10           In another embodiment of the invention, the therapeutically effective compound is selected from the group consisting of magnesium, magnesium acetate, magnesium ascorbate, magnesium carbonate, magnesium chloride, magnesium citrate, magnesium stearate, magnesium gluconate, magnesium hydroxide, magnesium salicylate, magnesium sulfate and magnesium oxide.

15           In another embodiment of the invention, the therapeutically effective compound is selected from the group consisting of aluminum, aluminum acetate, aluminum carbonate, aluminum chloride, aluminum potassium sulfate, aluminum glycinate, aluminum hydroxide, aluminum lactate, aluminum oxide, aluminum subacetate, aluminum sulfate and aluminum phosphate.

20           In another embodiment of the invention, the therapeutically effective compound is selected from the group consisting of calcium, calcium acetate, calcium alginate, calcium benzoate, calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium hydroxide, calcium lactate, calcium phosphate, calcium stearate, calcium sulfate and calcium oxide.

25           In another embodiment of the invention, the therapeutically effective compound is selected from the group consisting of copper, copper gluconate and copper sulfate.

          In one embodiment of the invention, the therapeutically effective compound is selected from the group consisting of titanium, titanium dioxide, titanium peroxide, titanium salicylate and titanium tannate.

30           In another embodiment of the invention, the therapeutically effective compound is selected from the group consisting of iron, ferric chloride, ferric

citrate, ferric oxide, ferrous ascorbate, ferrous carbonate, ferrous sulfate, ferrous gluconate, ferrous fumarate, ferrous glycine sulfate and ferrous lactate.

In another embodiment of the invention, the therapeutically effective compound is selected from the group consisting of barium, barium carbonate,  
5 barium chloride, barium hydroxide and barium sulfate.

In a preferred embodiment of the invention, the polyvalent metal compound is magnesium (e.g., magnesium sulfate). Applicant has found magnesium to be very effective in treating and preventing aphthous ulcers or herpes simplex lesions, in treating pre-ulceration or pre-lesion symptoms, such  
10 as pain and inflammation, and in treating post-ulceration or post-lesion symptoms. Additionally, magnesium possesses many preferred characteristics for polyvalent metals for use in the present invention, such as pleasant to taste, colorless, odorless, endogenous, non-toxic, non-irritating, inexpensive, and stable.

15 The polyvalent metal compounds can be formulated as pharmaceutical compositions and administered topically to a human patient in a variety of forms, including gels, ointments, creams, pastes, lotions, liquids (e.g., oral rinses such as mouth washes/rinses), a lozenge, a medicated bandage, a spray or any other form which is suitable for topical and effective administration to an oral or  
20 percutaneous ulcer/lesion.

For topical administration, the polyvalent metal compounds may be applied in pure form. However, it will generally be desirable to administer them to the mucosal surface or skin as compositions or formulations in combination with a suitable dermatologically or pharmaceutically acceptable carrier, which  
25 may be a solid or a liquid. (A suitable dermatologically or pharmaceutically acceptable carrier includes any dermatologically or pharmaceutically acceptable carrier which is capable of mixture with a polyvalent metal compound.)

Useful solid carriers include carboxymethylcellulose or derivatives thereof, Carbopol® polymers, polyacrylic acid polymer, gelatin or a mixture  
30 thereof. Useful liquid carriers include water, glycerin, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved

or dispersed at effective levels, optionally with the aid of non-toxic surfactants. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, sprayed onto the affected area using pump-type or aerosol sprayers, or used as mouth rinses.

5           In a preferred embodiment, the medicament which is administered to a patient comprises a polyvalent metal compound and a bioadhesive or mucoadhesive paste. Generally, dosage forms that comprise bioadhesives and/or mucoadhesives provide prolonged (about 1 hour to about 8 hours) direct contact with the damaged and/or diseased (e.g., pre-ulcerous and/or post-  
10 ulcerous) tissue area.

Use of a spatula (e.g., applicator) or similar device can facilitate application or administration of the paste, gel or ointment, especially in areas difficult to reach by inserting the finger. The spatula or similar device can be made of metal, plastic, or wood. The applicator is more hygienic and may  
15 perform better than a finger in administering or spreading the product (e.g., the paste, gel or ointment) to the lesion in all areas.

Drying of the tissue area of lesion with a clean paper, tissue, cotton tip, or gauze before administration of a medicament of the invention can facilitate close contact, maintain high drug concentrations at the lesion site and hence  
20 enhance the efficacy of the treatment. In order to minimize dilution of medicaments by the saliva continuously formed in the mouth cavity and to achieve the maximum therapeutic benefit, after topical administration, patients should have the mouth open slightly in a lying down, sitting or standing position. With the mouth open, the saliva produced can more easily flow  
25 directly into the stomach without accumulation in the mouth cavity.

Administration of medicament shortly before going to bed is preferred because a more prolonged contact between the drug and the lesion can result during sleep. Additionally, even though the patient may be symptom free by the following morning, the patient should continue topical application of the medicament after  
30 breakfast and again after lunch to reduce the possibility of "flare-ups" during the second day as a result of the vulnerability of freshly-recovered lesion to "stress"

from the day. The chance of the flare-ups is reduced by using a combination of a polyvalent metal compound and an anti-inflammatory compound. Patients should avoid eating, drinking and talking after medication as long as possible (for example, about one hour) due to a possibility of washing or moving the drug  
5 away from the administration site. Protection of medicament in the mouth by inserting a piece of gauze may be valuable under certain circumstances. During or shortly after treatment, the patient should avoid eating foods or doing activities known to provoke the disease or symptoms.

When using a liquid mouth rinse/wash, the patient should first swirl the  
10 medicament in the mouth for several seconds (to ascertain contact between the medicament and the surface of the lesion) and hold the medicament in the mouth for as long as possible (from a few minutes to about 10 minutes) by closing the mouth. After spitting out the diluted medicament, the patient should not drink or eat for about 30 to about 60 minutes to allow a longer time of contact between  
15 the medicament and the surface of the lesion in the mouth. To enhance the contact time between the medicament and the surface lesion, a viscosity-enhancing agent, such as Carbopol®, glycerin and carboxymethylcellulose or a derivative thereof, may also be incorporated into the mouth rinse. A fragrance, coloring agent and/or a preservative may also be added to the mouth rinse. In a  
20 preferred embodiment, a patient is first treated with a mouth rinse and then treated with a paste application.

Suitable methods for preparing gels, ointments, creams, pastes, lotions, liquids (e.g., oral rinses such as mouth washes/rinses), lozenges, medicated bandages, or sprays suitable for topical and effective administration to an oral or  
25 percutaneous ulcer or lesion or to an area demonstrating pre-ulcerous or pre-lesion conditions are known in the art and are illustrated in the Examples.

Generally, the concentration of a polyvalent metal compound in a liquid, semi-solid, or solid composition will be about 0.01% to about 10%, preferably about 0.1% to about 10%, more preferably about 0.01% to about 3.5%, more  
30 preferably 0.03% to about 2.5%, and more preferably about 0.05% to about 2.0% weight by volume. In a preferred embodiment the polyvalent metal

compound(s) is present in the pharmaceutical compositions/medicaments in amounts ranging from about 0.01% to about 30%, preferably from about 0.02% to about 3% weight by volume.

In a preferred embodiment an anti-inflammatory compound is  
5 administered in combination with a polyvalent metal compound. Anti-inflammatory compounds include glucocorticoidal steroids such as hydrocortisone, prednisolone, dexamethasone, or triamcinolone acetonide, as well as nonsteroidal anti-inflammatory drugs (NSAIDs), such as salicylate, ibuprofen, naproxen, acetaminophen, indomethacin or ketoprofen. In one  
10 embodiment, the anti-inflammatory compound is hydrocortisone or hydrocortisone acetate. The inclusion of an anti-inflammatory compound markedly enhances the therapeutic activity, including the prevention and treatment of pre- and post ulceration symptoms and conditions, of the polyvalent metal compounds. Effective anti-inflammatory compounds without the need of  
15 a prescription are preferred.

Additionally, topical administration of nonsteroidal anti-inflammatory compounds and/or low-potency glucocorticoidal steroids, such as hydrocortisone, hydrocortisone acetate, cortisone or cortisone acetate, without the addition of a polyvalent metal compound is also beneficial in preventing  
20 aphthous ulcers or herpes simplex lesions and in treating their pre-ulceration symptoms. Generally, the concentration of an anti-inflammatory compound in a liquid, semi-solid, or solid composition will be about 0.01 to about 2%, more preferably about 0.05% to about 0.5% weight by volume.

It is understood that the meaning of the phrase "an effective amount of  
25 one or more polyvalent metal compounds" is an amount of one or more polyvalent metal compounds that is effective to reduce or diminish the size of the lesion, ulcer and/or inflamed tissue area, shorten the time for relief from the symptoms, and/or cause a reduction in the symptoms of aphthous ulcers or herpes simplex lesions. For instance, the methods of the present invention  
30 relieve pre-ulceration and pre-lesion symptoms as well as ulcers, lesions, post-ulceration and post-lesion symptoms and conditions, including pain,

inflammation, irritation, and discomfort, within about 5 to about 20 minutes after topical administration of the polyvalent metal compound(s) to the affected tissue. Additionally, the methods of the present invention heal or cause the ulcer, lesion or inflammatory bump to disappear within about 5 hours or about 8 hours to about 24 hours after topical administration of the polyvalent metal compound. This is in sharp contrast with conventional drug therapy. Resolution of pain and healing of aphthous ulcers and/or herpes simplex lesions by conventional methods of treatment generally requires several days of continuous (3-to-4-times-a-day) treatment.

It is emphasized that the surprising and unexpected efficacy of polyvalent metal compounds for the prophylaxis, treatment and/or cure of aphthous ulcers and herpes simplex lesions described herein can be attributed to the hitherto unreported combined effects of their analgesic, anti-inflammatory, anti-microbial and tissue-regenerating properties.

The invention will now be illustrated by the following non-limiting Examples.

### **Example I**

#### **Prophylaxis and Treatment of Aphthous Ulcers using Pepto-Bismol® (Bismuth Subsalicylate)**

Pepto-Bismol® (Proctor and Gamble, Cincinnati, Ohio) is a commercial nonprescription suspension product containing 262 mg of bismuth subsalicylate per tablespoon (15 ml) as the active ingredient (*i.e.*, 1.75%). The product label for Pepto-Bismol® states that its recommended use is for the treatment of upset stomach, indigestion, nausea, heartburn and diarrhea. The normal dose for adults is 30 ml, which may be repeated every 0.5 to 1.0 hour for a total of 8 doses (*i.e.*, 240 ml) in one day.

Prior to bedtime, a small amount of Pepto-Bismol®, which had been concentrated through evaporation, was administered several times to the surface

area of a painful aphthous ulcer (about 0.30 cm in size), which developed under a human tongue three days earlier. The following morning, there was no longer any pain associated with the lesion. The "concentrated" Pepto-Bismol® was administered twice more that day, after which, the lesion was healed. The

5 concentrated Pepto-Bismol® suspension has also been used to quickly reverse further development of the early (no visible exudate) stages of aphthous ulcers.

### Example II

#### Treatment of Pre-Ulceration Symptoms and Prophylaxis 10 of Aphthous Ulcers Using Bismuth Citrate Oral Paste A (Gel)

A water-based oral paste A containing 1% bismuth citrate as an active ingredient was prepared. The paste also contained about 30% glycerin, 1% sodium bicarbonate, 1% Carbopol® ULTREX-10 (a polyacrylic acid polymer used as a thickening, bioadhesive or mucoadhesive agent) and 63% water. The

15 paste was administered to two inflammatory, painful bumps around the tongue and to a painful lesion on the floor of the oral cavity after drying these areas with clean tissue paper before bedtime. The pain literally stopped in a few minutes, and almost complete healing was noted the next morning.

20

### Example III

#### Treatment of Pre-Ulceration Symptoms and Prophylaxis 25 of Aphthous Ulcers Using Bismuth Citrate and Naproxen Oral Paste A

A water-based paste containing 1% bismuth citrate and 0.5% sodium

25 naproxen with sodium carboxymethylcellulose as a thickening agent was prepared. A small amount of this paste was administered before bedtime to two aphthous ulcers of the tongue at the onset of development. The following morning, there were no longer any symptoms of the disease, and no further administration was needed. This novel treatment regimen was repeated

30 successfully two more times.

**Example IV****Treatment of Aphthous Ulcer Using Bismuth Citrate/****Hydrocortisone Oral Paste A**

A water-based oral paste containing about 0.6% bismuth citrate, 0.8% hydrocortisone, 27% glycerin, 61% water and 11% Carbopol® ULTREX-10 was prepared. Prior to bedtime, the area surrounding a small aphthous ulcer on the tip of a human tongue was dried with a cotton tip. Next, a small amount of the oral paste was administered to the lesion and the surrounding area. The following morning, there were no longer any symptoms of the disease.

10

**Example V****Treatment of Gingivitis Using Bismuth Citrate/Hydrocortisone Oral****Paste A**

Prior to bedtime, a small amount of the bismuth citrate/hydrocortisone oral paste A described in Example IV was administered to a swollen, painful to the touch, magenta gingivitis developed under two human teeth of the upper-left, front gum (the affected area was dried with cotton tip or ball prior to administration of the paste). The following morning, there was substantial improvement in the symptoms. The symptoms of the gingivitis no longer existed after administration of the oral paste two to three times a day for four days. A stainless steel spatula was used to assist in the administration of the paste.

25

**Example VI****Treatment of Ulcerative Gingivitis Using Bismuth Citrate****/Hydrocortisone Oral Paste A**

Upon the development of a gingival ulcer with diffuse bleeding in the lower left gum of a human mouth, the oral paste, as described in Example IV, was administered prior to bedtime. The next morning, the gum was no longer bleeding.

30

After further administration (twice a day for two days), the redness of the surrounding gingiva disappeared, the color returned to normal, and the size of the lesion was found to be approximately reduced by half (from about 0.4 mm to about 0.2 mm in length). Furthermore, after administration of the oral paste for  
5 three more days there was no pain or bleeding after probing the affected area with a toothpick. Additionally, the depth of the lesion appeared to be markedly reduced, and the affected area looked much healthier. Administration of medicament was facilitated by using a stainless spatula.

10

### Example VII

#### **Prophylaxis and Treatment of Aphthous Ulcers**

#### **with Bismuth Citrate/Hydrocortisone Oral Paste B**

A lower strength of bismuth citrate (0.2%) and hydrocortisone (0.2%) oral paste B was also prepared similar to that described in Example II. A small  
15 amount of oral paste B was administered to an aphthous ulcer on the tip of a human tongue, after drying the affected lesion area with tissue paper, prior to bed. The pain stopped almost immediately. The next morning, the ulcer, and its associated pain, were no longer present.

A single overnight administration of oral paste B was also successful to  
20 prevent the full development of an aphthous ulcer in a human. Upon the sensation of a mild stinging pain, an early sign of an aphthous ulcer, on the tip of a human tongue, oral paste B was administered overnight. In the morning, the stinging sensation no longer existed and the patient did not develop a full aphthous ulcer. Thus, the early administration of medicaments of the present  
25 invention may effectively prevent a later painful full-blown development of aphthous ulcers.

### Example VIII

#### **Treatment of Gingivitis with Bismuth Citrate/Hydrocortisone Oral Paste B**

Oral paste B was administered two times a day to an area of gingivitis in a human for three days. After administration of this treatment, the gingival color  
5 returned to normal and the area no longer bled upon probing.

### Example IX

#### **Prophylaxis and Treatment of Aphthous Ulcers with**

#### **Aluminum Hydroxide/Magnesium Hydroxide Oral Paste C**

10 Oral paste C containing 0.25% aluminum hydroxide and 0.25% magnesium hydroxide was prepared similar to that of above oral paste B. After drying the tip of a human tongue with clean tissue paper, a small amount of oral paste C was administered to an area of demonstrating early signs (pre-ulcer stage) of a canker sore area before going to bed. The pain disappeared in a few  
15 minutes after administration. The inflammatory bump disappeared by the next morning. Similar results were obtained on other occasions.

### Example X

#### **Treatment of Aphthous Ulcer with Zinc Acetate Oral Paste D**

20 Oral paste D containing 0.25% zinc acetate was prepared similar to that of oral paste B. A stinging pain with a small ulcer was noticed under the tongue of a human subject. At midnight, after drying the area with a clean paper tissue, a small amount of oral paste D was administered to the lesion and the pain stopped almost immediately. No pain was felt and the lesion was practically  
25 healed next morning. It is to be noted that administration of a placebo oral paste had no effect on relieving pain of the canker sore.

**Example XI****Treatment of Pre-Ulcerous Symptoms of Aphthous Ulcers  
with Aluminum Potassium Sulfate Oral Paste E**

Oral paste E containing about 0.25% aluminum potassium sulfate (i.e.,  
5 alum) was prepared similar to oral paste B. The pH was adjusted to 4.8 with  
sodium carbonate. A painful bump (early stage of a canker sore) was noted in  
the right front edge of the tongue of a human subject. Oral paste E was  
administered to the affected area before bedtime. The pain from the pre-  
ulcerous symptom stopped within a few minutes after administration of Oral  
10 paste E. Next morning, the paste was administered two more times. The bump  
and pain disappeared before noon.

**Example XII****Treatment of Painful Bumps of Aphthous Ulcers  
with Magnesium Sulfate Oral Paste F**

15 Oral paste F containing 0.5% anhydrous magnesium sulfate was  
similarly prepared as oral paste E. A sizable red bump (pain upon touch) on the  
tongue of a human subject was treated with oral paste F before bedtime. The  
bump disappeared by the next morning. Similar pastes containing 1% or 4%  
20 magnesium sulfate were also found to be similarly effective after one application  
prior to bedtime.

**Example XIII****Treatment of Pre-Ulceration Symptoms of Aphthous Ulcer  
with Ferric Citrate Oral Paste G**

25 Oral paste G containing 0.15% ferric citrate was similarly prepared as  
oral paste E. A single administration of oral paste G before bedtime was found  
to effectively treat the bump on a tongue on two occasions in a human subject.

30

**Example XIV****Treatment of Painful Aphthous Ulcers  
with Magnesium Sulfate Oral Paste H**

A 4.0% magnesium sulfate paste (the pH was adjusted to about 6.0 with sodium hydroxide) with Carbopol® 974P as a mucoadhesive agent was prepared and applied to an about 0.5cm size of aphthous ulcer on left top side of the tongue in a human subject before bedtime. The pain disappeared in about 15 minutes and no pain was felt the next morning. After eating breakfast, the paste was applied again and the aphthous ulcer was completely healed after the second application.

**Example XV****Treatment of Two Painful Aphthous Ulcers and an Erythematous Bump  
with Magnesium Sulfate and Hydrocortisone Acetate Oral Paste I**

Oral paste I containing 3.0% magnesium sulfate and 0.2% hydrocortisone acetate with Carbopol 974P (BF Goodrich, Cleveland, OH) was prepared. A human patient developed two painful medium-sized aphthous ulcers, one on the top surface of the tongue and the other underneath the tongue. The pain severely affected the eating and talking capabilities of the patient. Oral paste I was applied before dinner to both ulcerous areas. The pain completely disappeared within about 20 minutes and the patient was able to talk and eat throughout dinner without any pain. Oral paste I was applied again prior to bedtime. Both ulcers were found to be reduced in size the next morning and there was no pain. The paste was applied again after breakfast, after lunch and prior to bed. No pain was felt through the day and both ulcers were found to be completely healed/cured the next morning. No "flare up" or recurrence of the aphthous ulcer developed.

Oral paste I was also used to completely heal a small erythematous (e.g., redness of the mucosal tissue of the oral cavity caused by dilatation and congestion of the capillaries) bump with only one application prior to bed.

The safety of the above paste is obvious from the fact that both magnesium and hydrocortisone are endogenous substances and the amounts of the drugs present in the paste is minute compared to those normally present in the human body.

5

### Example XVI

#### A Desirable Paste Formula for Treating

#### Aphthous Ulcers, Gingivitis or Herpes Simplex Lesions

In view of the above results, one potentially desirable formula for treating aphthous ulcers, gingivitis or herpes simplex lesions has the following ingredients:

|    |                                           |       |
|----|-------------------------------------------|-------|
|    | Bismuth citrate (colloidal form). . . . . | 0.2%  |
|    | Magnesium sulfate. . . . .                | 4.0%  |
| 15 | Zinc sulfate. . . . .                     | 0.1%  |
|    | Hydrocortisone acetate. . . . .           | 0.02% |
|    | Glycerin. . . . .                         | 60%   |
|    | Water. . . . .                            | 30%   |
|    | Carbopol®. . . . .                        | 5.0%  |
| 20 | Sodium hydroxide for adjusting pH to 7.0  |       |

### Example XVII

#### Treatment of Irritating and Inflammatory Bumps with

#### a 2.5% Magnesium Sulfate Mouth Rinse

A human subject had two small irritating inflammatory bumps (pre-ulcerous symptom) at the tip of the tongue for about two days. Approximately 30 minutes prior to bedtime, the subject rinsed his mouth by swirling about 10 ml of an aqueous 2.5% magnesium sulfate solution for about 10 seconds and holding it in his mouth for about 8 minutes prior to spitting it out. This mouth rinse was repeated two more times prior to bedtime. After about 7 hours of sleep, the two bumps were completely disappeared and no flare-up or recurrence occurred. Thus, the inflammatory and irritating bumps were completely healed/cured after 3 mouth rinses prior to bedtime. The mouth rinse was prepared by dissolving 2.5 grams of anhydrous magnesium sulfate in 100 ml of distilled water.

35

**Example XVIII****Treatment of Herpes Simplex Lesions with a Paste Containing  
Magnesium Sulfate, Alum, and Bismuth Citrate**

5 A paste containing 0.5% magnesium sulfate, 1% alum and 0.2% bismuth  
citrate was similarly prepared. The paste was applied two to three times a day to  
a herpes simplex lesion on a human subject. After application, no pain was  
noticed and the lesion completely healed in about 3 days.

**Example XIX**

10 **Treatment of Pre-Ulceration Symptoms and Prophylaxis of  
Aphthous Ulcers with a Novel Ultra-Low-Strength Hydrocortisone or  
Hydrocortisone Acetate Paste**

A paste containing 0.02% of hydrocortisone or hydrocortisone acetate  
using Carbopol® as a mucoadhesive agent was also similarly prepared. In one  
15 patient, these pastes have been repeatedly demonstrated to almost immediately  
(within about 10 to 20 minutes) and completely relieve the pain of inflammatory  
bumps or lesions after one single application before bedtime. Furthermore, the  
bumps were found to disappear next day following one additional application in  
the morning. No development of more serious aphthous ulcers occurred later.  
20 The strength of the steroid used above is much less than that (usually 0.1%) of  
high-potency steroids, such as triamcinolone acetonide, used conventionally; the  
strength employed is regarded as the "subtherapeutic" strength based on  
conventional steroid therapy..

25 **Example XX**

**Surprising Result of Treatment of Percutaneous Fissure or Crack  
with Magnesium Sulfate Paste**

A human subject had a percutaneous fissure or crack (about 1 cm long  
and about 0.2 cm wide) in the lower leg. A 1% magnesium sulfate paste was  
30 applied to the fissure and covered with a bandage before bedtime. The pain

completely disappeared and the fissure was completely healed (re-epithelialization) by the morning.

It is to be understood that the above descriptions are intended to be  
5 illustrative, and not restrictive. Many other equivalents will be apparent to those  
of skill in the art upon reading and understanding the above description.  
Additionally, one skilled in the art will be able to ascertain, with no more than  
routine experimentation, many equivalents to the specific embodiments  
described herein. These equivalents are intended to be encompassed by the  
10 following claims.

All publications, patents, and patent documents are incorporated by  
reference herein, as though individually incorporated by reference.

**What is claimed is:**

1. The use of an effective amount of a salt or oxide of one or more  
polyvalent metals to prepare a medicament useful for:
  - a) preventing an aphthous ulcer on a mucosal surface of a mammal;
  - b) treating an aphthous ulcer on a mucosal surface of a mammal wherein  
the medicament comprises a mucoadhesive paste;
  - c) treating one or more pre-ulceration symptoms of an aphthous ulcer on  
a mucosal surface of a mammal;
  - 10 d) treating a herpes simplex lesion on the skin of a mammal wherein the  
polyvalent metal is not zinc; or
  - e) preventing a herpes simplex lesion on the skin of mammal wherein the  
polyvalent metal is not zincwherein for a polyvalent metal salt the counter-ion of the metal is not an  
15 agent known to provide the stated therapeutic effect.
2. The use of claim 1, wherein the salt or oxide is a bismuth compound,  
zinc compound, magnesium compound, aluminum compound, calcium  
compound, titanium compound, iron compound, copper compound or  
20 barium compound.
3. The use of claim 2, wherein the magnesium compound is magnesium,  
magnesium acetate, magnesium ascorbate, magnesium carbonate,  
magnesium chloride, magnesium citrate, magnesium stearate,  
25 magnesium gluconate, magnesium hydroxide, magnesium salicylate,  
magnesium sulfate or magnesium oxide.
4. The use of claim 1, wherein the medicament comprises a mucoadhesive  
agent.

30

5. The use of claim 4, wherein the mucoadhesive agent allows direct contact between the polyvalent metal and the mucosal surface for about 1 hour to about 8 hours after administration of the polyvalent metal.
- 5 6. The use of claim 1, wherein the medicament is formulated as a mouth rinse or wash.
7. The use of claim 1, wherein the medicament further comprises one or more anti-inflammatory compounds.
- 10 8. The use of claim 8, wherein the anti-inflammatory compound is a glucocorticoid steroid.
9. The use of claim 8, wherein the glucocorticoid steroid is hydrocortisone or hydrocortisone acetate.
- 15 10. The use of claim 8, wherein the anti-inflammatory compound is a non-steroidal anti-inflammatory drug.
- 20 11. The use of claim 1, wherein the metal compound comprises about 0.1% to about 10% weight by volume of the medicament.
12. The use of claim 1, wherein the medicament is useful for relieving pre-ulceration or pre-lesion symptoms within about 5 minutes to about 20 minutes after topical administration of the medicament to the mucosal or skin surface.
- 25 13. The use of claim 1, wherein the medicament is useful for healing the pre-ulceration symptoms within about 5 hours to about 24 hours after topical administration of the medicament to the mucosal or skin surface.
- 30

14. The use of claim 1, wherein the medicament is useful for relieving pain, inflammation or irritation associated with the ulcer or lesion within about 5 minutes to about 20 minutes after administration of the medicament.
- 5 15. The use of claim 1, wherein the medicament is useful for healing a lesion or ulcer within about 8 hours to about 24 hours after administration of the medicament.
16. The use of claim 1, wherein the medicament is suitable for  
10 administration one or more times.
17. The use of an effective amount of hydrocortisone, hydrocortisone acetate, cortisone or cortisone acetate in a mucoadhesive paste to prepare a medicament useful for preventing an aphthous ulcer on a mucosal  
15 surface of a mammal.
18. The use of an effective amount of hydrocortisone, hydrocortisone acetate, cortisone or cortisone acetate in a mucoadhesive paste to prepare a medicament useful for treating one or more pre-ulceration symptoms of  
20 an aphthous ulcer on a mucosal surface of a mammal.
19. A method for preventing an aphthous ulcer on a mucosal surface of a mammal comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals to a mucosal surface  
25 demonstrating pre-ulceration symptoms so as to prevent the ulcer.
20. A method for treating an aphthous ulcer on a mucosal surface of a mammal comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals in a mucoadhesive paste to the  
30 ulcer.

21. A method for treating one or more pre-ulceration symptoms of an aphthous ulcer on a mucosal surface of a mammal comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals to a mucosal surface demonstrating pre-ulceration symptoms.
22. A method for treating a herpes simplex lesion on the skin of a mammal comprising topically administering an effective amount of a salt or oxide of a polyvalent metal to a mammal in need of such treatment, where the polyvalent metal is not zinc.
23. A method for preventing a herpes simplex lesion on the skin of a mammal comprising topically administering an effective amount of a salt or oxide of a polyvalent metal to an area of skin demonstrating pre-lesion symptoms so as to prevent the lesion, where the polyvalent metal is not zinc.
24. The use of an effective amount of a salt or oxide of one or more polyvalent metals to prepare a medicament useful for:
- a) preventing or treating oral ulcers of a mammal resulting from chemotherapy or radiation therapy; or
- b) providing relief of pain and healing of burned tissue of a mammal.
25. A method for the prophylaxis or treatment of oral ulcers of a mammal resulting from chemotherapy or radiation therapy comprising topically administering an effective amount of a salt or oxide of one or more polyvalent metals to a mucosal surface likely to suffer or suffering from ulcer formation.
26. A method for providing relief of pain and promotion of wound healing of burned tissue of a mammal comprising topically administering an

effective amount of a salt or oxide of one or more polyvalent metals to the affected burned tissue.

27. The method of claim 26, wherein the salt or oxide is formulated as a  
5 solution, a liquid, a spray, or a gel.
28. The method of claim 27, further comprising at least about 30% or more by weight glycerin.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/18223

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A 61 K 33/34, 33/32, 33/24, 31/56

US CL : 424/643, 630, 653, 638; 514/177

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/643, 630, 653, 638; 514/177

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
STN (embase, biosis, medline, caplus, uspatfull)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|------------------------------------------------------------------------------------|-----------------------|
| Y          | US 5,981,499 A (HAU) 09 November 1999 (09.11.1999), entire document.               | 1-28                  |
| Y          | US 5,514,667 A (CULIS-HILL) 07 May 1996 (07.05.1996), entire document.             | 1-28                  |
| Y          | US 5,376,636 A (RUTHERFORD et al) 27 December 1994 (27.12.1994), entire document.  | 1-28                  |

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

|                                                                                                                                                                         |                                                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>* Special categories of cited documents:</p>                                                                                                                         |                                                                                                                                                                                                                                                  |
| "A" document defining the general state of the art which is not considered to be of particular relevance                                                                | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                                              |
| "B" earlier application or patent published on or after the international filing date                                                                                   | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                                                                     |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means                                                                                            | "&" document member of the same patent family                                                                                                                                                                                                    |
| "P" document published prior to the international filing date but later than the priority date claimed                                                                  |                                                                                                                                                                                                                                                  |

Date of the actual completion of the international search

10 July 2002 (10.07.2002)

Date of mailing of the international search report

11 SEP 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Valerie Bell-Harris for  
Mimma Moezie

Telephone No. (703)308-1235